Ceralasertib

DB14917InvestigationalSmall molecule

Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase ATR
Curator reviewed
Formula / weight: C₂₀H₂₄N₆O₂S · 412.51 g/mol (avg)
Code names: ATR KINASE INHIBITOR AZD6738 · AZD-6738 · WHO 10842

Resolves to

Compound

Structure

InChIKeyDTTJKLNXNZAVSM-JYCIKRDWSA-NSMILESC[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)[S@](C)(=N)=O)C1=CN=CC2=C1C=CN2

Targets

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

45Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ceralasertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.